⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1345798 | 0.80 | — | — | |
| SCHEMBL4654247 | 0.76 | FAAH (0.41) | — | |
| SCHEMBL5133204 | 0.75 | TAS1R3 (0.50) | — | |
| SCHEMBL21813866 | 0.73 | — | — | |
| SCHEMBL331801 | 0.73 | — | — | |
| SCHEMBL851936 | 0.73 | — | — | |
| SCHEMBL1276410 | 0.73 | HDAC1 (0.39) | — | |
| Oxalic Acid SCHEMBL1420324 | 0.73 | ALOX15 (0.43) | — | |
| SCHEMBL3627661 | 0.71 | — | — | |
| SCHEMBL6717845 | 0.71 | TAS1R3 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018141959-A1 | IMMUNOMODULATORY ANTIBODY DRUG CONJUGATES BINDING TO A HUMAN MICA POLYPEPTIDE | INNATE PHARMA (FR) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018138032-A2 | NKp46 BINDING AGENTS | INNATE PHARMA (FR) | 2018-08-02 | — | — | WO | disclosed |
| EP-3010547-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | Innate Pharma (FR) | 2016-04-27 | — | — | EP | disclosed |
| EP-2968582-A1 | SOLID PHASE TGASE-MEDIATED CONJUGATION OF ANTIBODIES | Innate Pharma (FR) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015155306-A1 | NEW TRPA1 ANTAGONISTS | ALMIRALL, S.A. (ES) | 2015-10-15 | — | — | WO | disclosed |
| WO-2014202773-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | INNATE PHARMA (FR) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014140300-A1 | SOLID PHASE TGASE-MEDIATED CONJUGATION OF ANTIBODIES | INNATE PHARMA (FR) | 2014-09-18 | — | — | WO | disclosed |
| EP-2675791-A1 | SUBSTITUTED 6,7-DIALKOXY-3-ISOQUINOLINOL DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE10A) | Allergan, Inc. (US) | 2013-12-25 | — | — | EP | disclosed |
| EP-2556067-A2 | PYRAZOLYL UREAS AS P38 MAP KINASE INHIBITORS | Respivert Limited (GB) | 2013-02-13 | — | — | EP | disclosed |
| EP-2509595-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | Respivert Limited (GB) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011124923-A2 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-10-13 | — | — | WO | disclosed |
| EP-2370451-A2 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | Chiralgen, Ltd. (JP) | 2011-10-05 | — | — | EP | disclosed |
| WO-2011070368-A1 | ANTIVIRAL USE OF UREA COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070369-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2010129057-A2 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010064146-A2 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | CHIRALGEN, LTD. (JP) | 2010-06-10 | — | — | WO | disclosed |
| EP-1898903-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006135627-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2006-12-21 | — | — | WO | disclosed |
| EP-1658066-A2 | ADAMANTYLGLYCINE- BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | Bristol-Myers Squibb Company (US) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005012249-A2 | ADAMANTYGLYCINE- BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-10 | — | — | WO | disclosed |